1
|
Nyenhuis SM, Dixon AE, Wood L, Lv N, Wittels NE, Ronneberg CR, Xiao L, Dosala S, Marroquin A, Barve A, Harmon W, Poynter ME, Parikh A, Camargo CA, Appel LJ, Ma J. Erratum to "The effects of the DASH dietary pattern on clinical outcomes and quality of life in adults with uncontrolled asthma: Design and methods of the ALOHA Trial" [Contemporary Clinical Trials 131 (2023) 107274]. Contemp Clin Trials 2024; 138:107373. [PMID: 38310039 PMCID: PMC10921235 DOI: 10.1016/j.cct.2023.107373] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2024]
Affiliation(s)
- S M Nyenhuis
- Section of Allergy and Immunology, University of Chicago, Chicago, IL, USA
| | - A E Dixon
- Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Vermont, Burlington, VT, USA
| | - L Wood
- University of Newcastle, Newcastle, Australia
| | - N Lv
- Department of Medicine, University of Illinois Chicago, Chicago, IL, USA
| | - N E Wittels
- Department of Medicine, University of Illinois Chicago, Chicago, IL, USA
| | - C R Ronneberg
- Department of Medicine, University of Illinois Chicago, Chicago, IL, USA
| | - L Xiao
- Department of Epidemiology and Population Health, Stanford University, Palo Alto, CA, USA
| | - S Dosala
- Department of Medicine, University of Illinois Chicago, Chicago, IL, USA
| | - A Marroquin
- Department of Medicine, University of Illinois Chicago, Chicago, IL, USA
| | - A Barve
- Department of Medicine, University of Illinois Chicago, Chicago, IL, USA
| | - W Harmon
- Department of Medicine, University of Illinois Chicago, Chicago, IL, USA
| | - M E Poynter
- Department of Medicine, University of Illinois Chicago, Chicago, IL, USA
| | - A Parikh
- Department of Medicine, University of Illinois Chicago, Chicago, IL, USA
| | - C A Camargo
- Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Department of Emergency Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
| | - L J Appel
- Welch Center for Prevention, Epidemiology and Clinical Research, The Johns Hopkins University, Baltimore, MD, USA
| | - J Ma
- Department of Medicine, University of Illinois Chicago, Chicago, IL, USA.
| |
Collapse
|
2
|
Ratanchandani KK, Kulshrestha A, Shah SP, Bhuvana J, Parikh A, Kunikullaya S. A Comparative Analysis of Effect of HIV Infection on Outcomes of Cervical Cancer Treated with Radiotherapy. Int J Radiat Oncol Biol Phys 2023; 117:e539. [PMID: 37785665 DOI: 10.1016/j.ijrobp.2023.06.1830] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) There is paucity of data on management of human immunodeficiency virus (HIV) positive cervical cancer and its clinical outcomes in Indian women. The primary objective of this study was to compare disease free survival (DFS) and overall survival (OS) between HIV-positive and HIV-negative patients receiving radiotherapy (RT) for cervical cancer. The secondary endpoints were toxicity and various factors affecting DFS and OS. MATERIALS/METHODS Patients diagnosed with cervical cancer on histopathology and treated with RT with or without concomitant chemotherapy (CT) at an institution between 2015 and 2020 were included in this retrospective analysis. On the basis of HIV serology test, 70 patients were included in each arm, Arm A had HIV-negative patients and Arm B had HIV-positive patients. In both the arms, external beam radiotherapy (EBRT) in adjuvant or radical setting was given with a total dose of 46-50 Gy to whole pelvis and iliac nodes; 2 Gy/fraction daily as 5 fractions/week by conventional four-field box technique or conformal 3-dimensional radiotherapy (3DCRT) or Intensity modulated radiotherapy (IMRT). Concurrent cisplatin was administered as weekly 40mg/m2 to patients with ECOG< = 2, creatinine clearance >40mL/min in radical and adjuvant patients as indicated. CD4 counts ≥200 cells/mm3 was a prerequisite for concurrent cisplatin in Arm B. Intracavitary or interstitial brachytherapy was delivered as indicated. Statistical analysis was done using statistical software. Kaplan-Meier method used for all survival analysis. Log rank test was used to calculate statistical significance for various prognostic factors followed by Cox regression test for multivariate analysis. RESULTS Median age was 46.5 years (range: 30-76). In Arm A, 62 patients (88.57%) and 5 patients (7.14%) received radical and adjuvant RT. In Arm B 61 patients (87.14%) and 2 patients (2.85%) were given radical and adjuvant RT. 66 patients (94.28%) in Arm A and 52 patients (74.28%) in Arm B received concurrent cisplatin. At a median follow up of 33.8 months (range: 1.2 to 85.4), 2-year DFS was 88.9% for Arm-A and 86.5% for Arm-B (p = 0.134) and 2-year OS was 91.4% and 82.9% for Arm-A and Arm-B (p = 0.001), respectively. Grade III/IV skin toxicity was seen in and 4 patients (5.71%) in Arm A and 12 patients (17.14%) in Arm B (p = 0.34). Grade III/IV gastrointestinal toxicity was seen in 2(2.85%) patients and 4(5.7%) patients in Arm A and Arm B respectively (p = 0.40). 14(20%) patients in Arm A and 27(38.5%) patients in Arm B had Grade III/IV hematologic toxicity (p = 0.016). On multivariate analysis, anemia (Hb≤12 gm/dl) and OTT ≥56 days were associated with unfavorable DFS (p = 0.03 and p = 0.001) and OS (p = 0.04 and p = 0.01) in Arm B. CONCLUSION In view of comparable DFS outcomes in both the arms, HIV-positive cervical cancer patients can be managed with the standard treatment protocol as HIV-negative patients. HIV-positive patients are more likely to experience poorer DFS and OS. However, results need to be validated on prospective study.
Collapse
Affiliation(s)
| | | | - S Patel Shah
- The Gujarat Cancer and Research Institute, Ahmedabad, India
| | - J Bhuvana
- The Gujarat Cancer and Research Institute, Ahmedabad, India
| | - A Parikh
- The Gujarat Cancer and Research Institute, Ahmedabad, India
| | - S Kunikullaya
- The Gujarat Cancer and Research Institute, Ahmedabad, India
| |
Collapse
|
3
|
Iv NB, Jain K, Parikh A, Rath S, Suryanarayan U, Ratanchandani KK. Correlation of Dose Volume Parameters with Dysphagia and Pharyngeal Constrictor Muscle Thickness in Dysphagia Optimized IMRT. Int J Radiat Oncol Biol Phys 2023; 117:e566-e567. [PMID: 37785732 DOI: 10.1016/j.ijrobp.2023.06.1891] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Reduced radiation dose to the pharyngeal constrictor muscles (PCM) using dysphagia optimized intensity-modulated RT (DO-IMRT) is associated with improved swallowing outcomes in oropharyngeal cancers (OPCs). Purpose was to evaluate the relationship between dose of radiation delivered and acute dysphagia in patients with OPC treated with IMRT, after delineation of PCM. MATERIALS/METHODS Twenty-five patients with newly diagnosed OPC who underwent definitive IMRT with concurrent cisplatin were included in the study. PCM mean dose < 50 Gy was used as the dose constraint. Target volume was divided into high, intermediate and low risk areas receiving doses in the range of 60-66 Gy, 54-58 Gy, 51-56 Gy in 30-33 fractions over 6-6.5 weeks, respectively. PCM dose-volume parameters were collected and logistic regression was used to analyze these data relative to percent weight loss during RT and duration of feeding tube use. Thickness of constrictor muscle in pre-treatment and 3 months post-therapy CT scan were assessed. Weekly assessment of dysphagia was based on RTOG toxicity gradings. Aim of the study was to evaluate the correlation between dysphagia grades with dose-volume parameters and PCM thickness. RESULTS Median age was 55.0 years (mean 54.3) with 24 males and stage II:III-16:9 patients. Dmean to PCM was 49.86 Gy (range 48.22 -57.63) with median Dmax of 70.24 Gy. For patients with dysphagia (grade ≥1), V50 ranged from 48.2-57.23%, while in those with no dysphagia, it ranged from 47.92-52.18 % (Mean 51.36%). Nine patients needed feeding tube after RT end. Median feeding tube duration was 64 days. The correlation between Dmean ≥ 50 Gy and dysphagia at 1st, 2nd, 3rd and 6th month was found statistically significant (p < 0.01). Table 1 shows the Pearson correlation and P-value of the dosimetric parameters with dysphagia. The correlation of V50 was found statistically significant with grade of dysphagia at 3rd and 6th month post-treatment (p<0.001). The mean thickness range and median thickness of constrictors before and 3 months after treatment were 1.8-3.2 mm, 2.4 mm, and 2.8-6.2 mm,4.1 mm, respectively. The increase in thickness of constrictor muscle correlated significantly (p<0.05) with dysphagia grades and also with V50, V60 and Dmean (p<0.001) but no statistical significance was seen with Dmax (p = 0.232). With a median follow-up of 18 months (range 7-24), 1-year actuarial local control was 92%. CONCLUSION DO-IMRT may prove beneficial in the OPC by preventing dysphagia and aspiration post therapy and hence improving the quality of life of patients. Dmean ≥ 50Gy, V50 > 51.4% and V60 > 35.5% are the parameters correlating significantly with dysphagia (p<0.001) and change in mean thickness of PCM (p<0.001).
Collapse
Affiliation(s)
- N Bathija Iv
- The Gujarat Cancer & Research Institute, Ahmedabad, India
| | - K Jain
- The Gujarat Cancer & Research Institute, Ahmedabad, India
| | - A Parikh
- The Gujarat Cancer and Research Institute, Ahmedabad, India
| | - S Rath
- Department of Radiation Oncology, Dr Ram Manohar Lohia Institute of Medical Sciences, Lucknow, India
| | - U Suryanarayan
- Department of Radiation Oncology, Gujarat Cancer Research Institute, Ahmedabad, India
| | | |
Collapse
|
4
|
Nyenhuis SM, Dixon A, Wood L, Lv N, Wittels N, Ronneberg CR, Xiao L, Dosala S, Marroquin A, Barve A, Harmon W, Poynter M, Parikh A, Camargo CA, Appel L, Ma J. The effects of the DASH dietary pattern on clinical outcomes and quality of life in adults with uncontrolled asthma: Design and methods of the ALOHA Trial. Contemp Clin Trials 2023; 131:107274. [PMID: 37380019 PMCID: PMC10629484 DOI: 10.1016/j.cct.2023.107274] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2023] [Revised: 05/31/2023] [Accepted: 06/25/2023] [Indexed: 06/30/2023]
Abstract
BACKGROUND Poor diet quality is an important risk factor for increased asthma prevalence and poor asthma control. To address the question of whether adults with asthma can benefit from following a healthy diet, this trial will test the efficacy and mechanisms of action of a behavioral intervention promoting the Dietary Approaches to Stop Hypertension (DASH) dietary pattern with sodium reduction among patients with uncontrolled asthma. METHODS In this 2-arm randomized clinical trial, 320 racially/ethnically and socioeconomically diverse adults with uncontrolled asthma on standard controller therapy will be randomized to either a control or an intervention group and assessed at baseline, 3, 6 and 12 months. Control and intervention participants will receive education on lung health, asthma, and other general health topics; additionally, the intervention group will receive DASH behavioral counseling over 12 months. The primary hypothesis is that the DASH behavioral intervention, compared with the education-only control, will lead to significantly more participants with minimum clinically important improvement (responders) in asthma-specific quality of life at 12 months. Secondary hypotheses will test the intervention effects on other asthma (e.g., asthma control, lung function) and non-asthma outcomes (e.g., quality of life). Additionally, therapeutic (e.g., short chain fatty acids, cytokines) and nutritional biomarkers (e.g., dietary inflammatory index, carotenoids) will be assessed to understand the mechanisms of the intervention effect. CONCLUSION This trial can substantially advance asthma care by providing rigorous evidence on the benefits of a behavioral dietary intervention and mechanistic insights into the role of diet quality in asthma. CLINICALTRIALS gov #: NCT05251402.
Collapse
Affiliation(s)
- S M Nyenhuis
- Section of Allergy and Immunology, University of Chicago, Chicago, IL, USA
| | - A Dixon
- Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Vermont, Burlington, VT, USA
| | - L Wood
- University of Newcastle, Newcastle, Australia
| | - N Lv
- Division of Academic Internal Medicine, Department of Medicine, University of Illinois Chicago, Chicago, IL, USA
| | - N Wittels
- Division of Academic Internal Medicine, Department of Medicine, University of Illinois Chicago, Chicago, IL, USA
| | - C R Ronneberg
- Division of Academic Internal Medicine, Department of Medicine, University of Illinois Chicago, Chicago, IL, USA
| | - L Xiao
- Department of Epidemiology and Population Health, Stanford University, Palo Alto, CA, United States of America
| | - S Dosala
- Division of Academic Internal Medicine, Department of Medicine, University of Illinois Chicago, Chicago, IL, USA
| | - A Marroquin
- Division of Academic Internal Medicine, Department of Medicine, University of Illinois Chicago, Chicago, IL, USA
| | - A Barve
- Division of Academic Internal Medicine, Department of Medicine, University of Illinois Chicago, Chicago, IL, USA
| | - W Harmon
- Division of Academic Internal Medicine, Department of Medicine, University of Illinois Chicago, Chicago, IL, USA
| | - M Poynter
- Division of Academic Internal Medicine, Department of Medicine, University of Illinois Chicago, Chicago, IL, USA
| | - A Parikh
- Division of Academic Internal Medicine, Department of Medicine, University of Illinois Chicago, Chicago, IL, USA
| | - C A Camargo
- Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Department of Emergency Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
| | - L Appel
- Welch Center for Prevention, Epidemiology and Clinical Research, The Johns Hopkins University, Baltimore, MD, USA
| | - J Ma
- Division of Academic Internal Medicine, Department of Medicine, University of Illinois Chicago, Chicago, IL, USA.
| |
Collapse
|
5
|
Sun Y, Baechler SA, Zhang X, Kumar S, Factor VM, Arakawa Y, Chau CH, Okamoto K, Parikh A, Walker B, Su YP, Chen J, Ting T, Huang SYN, Beck E, Itkin Z, McKnight C, Xie C, Roper N, Nijhawan D, Figg WD, Meltzer PS, Yang JC, Thomas CJ, Pommier Y. Targeting neddylation sensitizes colorectal cancer to topoisomerase I inhibitors by inactivating the DCAF13-CRL4 ubiquitin ligase complex. Nat Commun 2023; 14:3762. [PMID: 37353483 PMCID: PMC10290057 DOI: 10.1038/s41467-023-39374-9] [Citation(s) in RCA: 7] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2022] [Accepted: 06/09/2023] [Indexed: 06/25/2023] Open
Abstract
Colorectal cancers (CRCs) are prevalent worldwide, yet current treatments remain inadequate. Using chemical genetic screens, we identify that co-inhibition of topoisomerase I (TOP1) and NEDD8 is synergistically cytotoxic in human CRC cells. Combination of the TOP1 inhibitor irinotecan or its bioactive metabolite SN38 with the NEDD8-activating enzyme inhibitor pevonedistat exhibits synergy in CRC patient-derived organoids and xenografts. Mechanistically, we show that pevonedistat blocks the ubiquitin/proteasome-dependent repair of TOP1 DNA-protein crosslinks (TOP1-DPCs) induced by TOP1 inhibitors and that the CUL4-RBX1 complex (CRL4) is a prominent ubiquitin ligase acting on TOP1-DPCs for proteasomal degradation upon auto-NEDD8 modification during replication. We identify DCAF13, a DDB1 and Cullin Associated Factor, as the receptor of TOP1-DPCs for CRL4. Our study not only uncovers a replication-coupled ubiquitin-proteasome pathway for the repair of TOP1-DPCs but also provides molecular and translational rationale for combining TOP1 inhibitors and pevonedistat for CRC and other types of cancers.
Collapse
Affiliation(s)
- Yilun Sun
- Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA.
| | - Simone A Baechler
- Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA
| | - Xiaohu Zhang
- Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, 20850, USA
| | - Suresh Kumar
- Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA
| | - Valentina M Factor
- Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA
| | - Yasuhiro Arakawa
- Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA
| | - Cindy H Chau
- Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA
| | - Kanako Okamoto
- Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA
| | - Anup Parikh
- Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA
| | - Bob Walker
- Genetics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA
| | - Yijun P Su
- Advanced Imaging and Microscopy Resource, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, MD, 20892, USA
| | - Jiji Chen
- Advanced Imaging and Microscopy Resource, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, MD, 20892, USA
| | - Tabitha Ting
- Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA
| | - Shar-Yin N Huang
- Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA
| | - Erin Beck
- Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, 20850, USA
| | - Zina Itkin
- Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA
| | - Crystal McKnight
- Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA
| | - Changqing Xie
- Thoracic and GI Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA
| | - Nitin Roper
- Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA
| | - Deepak Nijhawan
- Advanced Imaging and Microscopy Resource, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, MD, 20892, USA
| | - William Douglas Figg
- Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA
| | - Paul S Meltzer
- Genetics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA
| | - James C Yang
- Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA
| | - Craig J Thomas
- Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, 20850, USA
| | - Yves Pommier
- Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA.
| |
Collapse
|
6
|
Mekhaimar M, Correa A, Hamo C, Doshi A, Young A, Roldan J, Lala A, Mitter S, Parikh A, Mancini D, Moss N. Glp-1 Receptor Agonists Among LVAD Patients with Diabetes and Obesity; Effect on Comorbid Conditions. J Heart Lung Transplant 2023. [DOI: 10.1016/j.healun.2023.02.1250] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/05/2023] Open
|
7
|
Mahmood K, Contreras J, Omar A, Fox A, Balboul Y, Lorente Ros M, Riasat M, Roldan J, Correa A, Pirlamarla P, Parikh A, Moss N, Anyanwu A, Gidea C. Achieving Equity in Minority Populations by Using the “Hub-And-Spoke” Model for Durable Left Ventricular Assist Devices. J Heart Lung Transplant 2023. [DOI: 10.1016/j.healun.2023.02.808] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/05/2023] Open
|
8
|
Cagliostro M, Folch A, Ali S, Lala-Trindade A, Moss N, Parikh A, Contreras J, Mitter S, Trivieri M, Gidea C, Mancini D, Barghash M. Added Value of Molecular Microscope Diagnostic System (mmdx) to Established Indicators of Heart Transplant Rejection: A Single Center Experience. J Heart Lung Transplant 2023. [DOI: 10.1016/j.healun.2023.02.1222] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/05/2023] Open
|
9
|
Feinman J, Parikh A, Behar J, Ashley K, Barghash M, Moss N, Lala-Trindade A, Anyanwu A, Natelson B, Mancini D. Low Incidence of Long COVID in Heart Transplant Recipients. J Heart Lung Transplant 2023. [PMCID: PMC10068072 DOI: 10.1016/j.healun.2023.02.429] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/05/2023] Open
|
10
|
Shivhare V, Rath S, Rathod H, Dash NK, Parikh A, Suryanarayan Kunikullaya U. Analyzing the impact of close margins and extra-resection margins on failure rates in postoperative oral cavity cancers. Klin Onkol 2023; 37:467-472. [PMID: 38158236 DOI: 10.48095/ccko2023467] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/03/2024]
Abstract
BACKGROUND Postoperative oral cancers with close margins belong to medium- to high-risk category for local failure. During re-surgery for close margins, there is sufficient doubt as to whether the re-excised tissue is from the same region as the close margin. Therefore, we planned a retrospective review of these cases of close margins that were re-excised with extra-resection margins (ERMs). MATERIAL AND METHODS Details of 2011 oral cavity patients resected at our hospital were retrieved. Cases with close margins were segregated and the status of ERMs was noted. The postoperative histopathological details, radiotherapy details, and failure patterns in all these cases were documented. The primary objective of the study was to assess the overall survival (OS) and disease-free survival (DFS) in cases with ERMs. The secondary objective was to assess the local and regional control rates and variation with the number and status of close and ERMs. OS, DFS, and local failure rates were defined from the date of registration. Statistical analysis was performed with the SPSS statistical software package. All survival analyses were performed using the Kaplan-Meier method. Log-rank test was used to test the statistical significance. A P-value of 0.05 was considered statistically significant. RESULTS Sixty-four cases with a median age of 47 years (range: 29-76) were considered for the final analysis. The median follow-up was 40 months (range: 9.5-56.5). The 2-year OS and DFS rates were 91.5% and 88.5%, respectively. The crude local and regional failure rates were 10.9% and 3.1%, respectively. The 3-year locoregional control rate was 90.2%. The 2-year locoregional control rate for one close margin was significantly better as compared to more than one close margin (P = 0.049). No difference in survival and failure rates was found between the number of ERMs resected (one vs. two) and ≤ vs. > 3 mm close margin status. Two patients developed bone metastases. CONCLUSION The survival rates and locoregional control rates did not differ much between the groups that had one or more ERMs. However, the locoregional control rates were better in cases with one close margin as compared to those with more than one close margin. A larger study with longer follow-up is needed to detect statistically significant differences in outcomes and identify the factors that portend poor prognosis in these cases with close margins and ERMs.
Collapse
|
11
|
Horinouchi H, Goldman J, Cho B, Tomasini P, Dunbar M, Hoffman D, Parikh A, Blot V, Camidge D. 387P Telisotuzumab vedotin (Teliso-V) in combination with osimertinib in patients with advanced EGFR-mutated, c-met overexpressing, non-small cell lung cancer (NSCLC): Safety and efficacy results from phase Ib study. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.10.424] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/07/2022] Open
|
12
|
Psaltis A, Chen AA, Longland R, Connolly DS, Brune CR, Davids B, Fallis J, Giri R, Greife U, Hutcheon DA, Kroll L, Lennarz A, Liang J, Lovely M, Luo M, Marshall C, Paneru SN, Parikh A, Ruiz C, Shotter AC, Williams M. Direct Measurement of Resonances in ^{7}Be(α,γ)^{11}C Relevant to νp-Process Nucleosynthesis. Phys Rev Lett 2022; 129:162701. [PMID: 36306775 DOI: 10.1103/physrevlett.129.162701] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/31/2021] [Revised: 07/01/2022] [Accepted: 08/24/2022] [Indexed: 06/16/2023]
Abstract
We have performed the first direct measurement of two resonances of the ^{7}Be(α,γ)^{11}C reaction with unknown strengths using an intense radioactive ^{7}Be beam and the DRAGON recoil separator. We report on the first measurement of the 1155 and 1110 keV resonance strengths of 1.73±0.25(stat)±0.40(syst) eV and 125_{-25}^{+27}(stat)±15(syst) meV, respectively. The present results have reduced the uncertainty in the ^{7}Be(α,γ)^{11}C reaction rate to ∼9.4%-10.7% over T=1.5-3 GK, which is relevant for nucleosynthesis in the neutrino-driven outflows of core-collapse supernovae (νp process). We find no effect of the new, constrained reaction rate on νp-process nucleosynthesis.
Collapse
Affiliation(s)
- A Psaltis
- Department of Physics and Astronomy, McMaster University, Hamilton, Ontario L8S 4M1, Canada
- The NuGrid Collaboration
| | - A A Chen
- Department of Physics and Astronomy, McMaster University, Hamilton, Ontario L8S 4M1, Canada
- The NuGrid Collaboration
| | - R Longland
- Department of Physics, North Carolina State University, Raleigh, North Carolina 27695, USA
- Triangle Universities Nuclear Laboratory, Duke University, Durham, North Carolina 27710, USA
| | - D S Connolly
- TRIUMF, 4004 Wesbrook Mall, Vancouver, British Columbia V6T 2A3, Canada
| | - C R Brune
- Department of Physics and Astronomy, Ohio University, Athens, Ohio 45701, USA
| | - B Davids
- TRIUMF, 4004 Wesbrook Mall, Vancouver, British Columbia V6T 2A3, Canada
- Department of Physics, Simon Fraser University, Burnaby, British Columbia V5A 1S6, Canada
| | - J Fallis
- North Island College, 2300 Ryan Road, Courtenay, British Columbia V9N 8N6, Canada
| | - R Giri
- Department of Physics and Astronomy, Ohio University, Athens, Ohio 45701, USA
| | - U Greife
- Department of Physics, Colorado School of Mines, Golden, Colorado 80401, USA
| | - D A Hutcheon
- TRIUMF, 4004 Wesbrook Mall, Vancouver, British Columbia V6T 2A3, Canada
| | - L Kroll
- Department of Physics and Astronomy, McMaster University, Hamilton, Ontario L8S 4M1, Canada
- The NuGrid Collaboration
| | - A Lennarz
- TRIUMF, 4004 Wesbrook Mall, Vancouver, British Columbia V6T 2A3, Canada
| | - J Liang
- Department of Physics and Astronomy, McMaster University, Hamilton, Ontario L8S 4M1, Canada
| | - M Lovely
- Department of Physics, Colorado School of Mines, Golden, Colorado 80401, USA
| | - M Luo
- Department of Physics and Astronomy, University of British Columbia, Vancouver, British Columbia V6T 1Z4, Canada
| | - C Marshall
- Department of Physics, North Carolina State University, Raleigh, North Carolina 27695, USA
- Triangle Universities Nuclear Laboratory, Duke University, Durham, North Carolina 27710, USA
| | - S N Paneru
- Department of Physics and Astronomy, Ohio University, Athens, Ohio 45701, USA
| | - A Parikh
- Department de Física, Universitat Politècnica de Catalunya, E-08036 Barcelona, Spain
| | - C Ruiz
- TRIUMF, 4004 Wesbrook Mall, Vancouver, British Columbia V6T 2A3, Canada
- Department of Physics and Astronomy, University of Victoria, Victoria, British Columbia V8W 2Y2, Canada
| | - A C Shotter
- School of Physics, University of Edinburgh EH9 3JZ Edinburgh, United Kingdom
| | - M Williams
- TRIUMF, 4004 Wesbrook Mall, Vancouver, British Columbia V6T 2A3, Canada
- Department of Physics, University of York, Heslington, York YO10 5DD, United Kingdom
| |
Collapse
|
13
|
McKean M, Barve M, Hong D, Parikh A, Rosen E, Yang J, Picard R, Yi J, Brail L, Vecchio D, Meniawy T, John T, Wang J. Preliminary results from FLAGSHP-1: A Phase I dose escalation study of ERAS-601, a potent SHP2 inhibitor, in patients with previously treated advanced or metastatic solid tumors. Eur J Cancer 2022. [DOI: 10.1016/s0959-8049(22)00890-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
14
|
Parikh S, Paula ADC, Bhaloo SI, Li A, Weigelt B, Patel K, Wronski A, Parikh A, Patel K, Reis-Filho J. Abstract 2949: Enabling single cell analysis of copy number variation in breast cancer. Cancer Res 2022. [DOI: 10.1158/1538-7445.am2022-2949] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Breast cancer is arguably one of the solid tumors most comprehensively analyzed by massively parallel sequencing. Although the repertoire of clonal somatic genetic alterations in primary and metastatic breast cancers has been characterized, a complete characterization of the subclonal genetic alterations present in these cancers, as well as their clonal composition and clonal dynamics remain to be fully defined. Addressing these knowledge gaps is germane to the successful personalization of treatments for breast cancer patients. Single cell sequencing is uncovering many insights into the clonal evolution and heterogeneity of breast cancers and how this can be leveraged for clinical and therapeutic benefit. Bulk next generation sequencing has primarily focused on mutation profiling; however, there are several lines of evidence to demonstrate the biological and clinical importance of accurately detecting copy number alterations. Previous single cell sequencing studies focusing on copy number alterations were based on whole-genome amplification methods or could not concurrently define the repertoire of somatic mutations and copy number alterations in single cells. Here we report on a novel single cell DNA sequencing approach leveraging the Tapestri device and Insights bioinformatic pipeline to detect both copy number alterations and somatic mutations in individual cells derived from breast cancer specimens. The identification of targeted somatic genetic alterations at single cell resolution provides novel insights about the development, progression and therapeutic resistance of breast cancers, and enables the development of novel diagnostic tools and predictive biomarkers.
Citation Format: Saurabh Parikh, Arnaud Da Cruz Paula, Shirin Issa Bhaloo, Alex Li, Britta Weigelt, Khushali Patel, Ania Wronski, Anup Parikh, Khushali Patel, Jorge Reis-Filho. Enabling single cell analysis of copy number variation in breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 2949.
Collapse
Affiliation(s)
| | | | | | - Alex Li
- 1Mission Bio, South San Francisco, CA
| | - Britta Weigelt
- 2Memorial Sloan Kettering Cancer Center, New York City, NY
| | | | | | | | | | | |
Collapse
|
15
|
Parikh S, Patel K, Li A, Parikh A. Abstract 6171: A single-cell solution for solid tumors to detect mutations and quantify copy number variations. Cancer Res 2022. [DOI: 10.1158/1538-7445.am2022-6171] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Cancer is a highly heterogeneous disease characterized by the presence of chromosomal structural copy number variation (CNV) and driver gene mutation events, which appear somatically at the early stages of oncogenesis and can drive tumor progression. Previously, we have developed a high throughput single cell DNA analysis platform that leverages droplet microfluidics and a multiplex-PCR based targeted DNA sequencing approach. It demonstrates high sensitivity detection of SNVs and indels in the same cells and generation of high resolution maps of clonal architecture based on mutational profiling. Here we expand upon the same approach and create an algorithm to accurately quantify CNVs along with genetic mutations from the same single cells. To estimate the CNV the amplicon read counts were corrected for artefacts related to cell to cell variability due sequencing efficiencies along with amplicon to amplicon variability that occur due to amplification efficiency differences. We used a spiked in diploid cell line as a reference to normalize all the cells. The spiked cell line was identified using its mutational profile. We validated the system using cell lines with known CNVs and found that we could at least accurately estimate copy numbers ranging from 0 through 5. Some of the regions were also validated orthogonally using droplet digital PCR. Another set of validation was performed using well characterized cell lines from NIST. We enable multiple visualizations of the copy number estimates in karyotype plots and line plots projected on SNV clones. With improved biochemistry, panel design and novel data analysis algorithms we develop a complete solution to detect amplification or loss of function in oncogenes and tumor suppressors reliably. Integration of CNVs and SNVs facilitates more accurate reconstruction of tumor evolution to better understand cancer progression mechanisms as well for quality control of gene edited cells, to further advance cancer research and therapy.
Citation Format: Saurabh Parikh, Khushali Patel, Alex Li, Anup Parikh. A single-cell solution for solid tumors to detect mutations and quantify copy number variations [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 6171.
Collapse
Affiliation(s)
| | | | - Alex Li
- 1Mission Bio Inc., South San Francisco, CA
| | | |
Collapse
|
16
|
Corcoran R, Tian J, Chen J, Chao S, Pelka K, Baiev I, Sindurakar P, Allen J, Meyerhardt J, Enzinger A, Enzinger P, McCleary N, Klempner S, Yurgelun M, Abrams T, Clark J, Ryan D, Giannakis M, Parikh A, Hacohen N. SO-38 Clinical efficacy and single-cell analysis of combined BRAF, MEK, and PD-1 inhibition in BRAFV600E colorectal cancer patients. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.04.436] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
17
|
Malukar S, Kunikullaya U, Parikh A, Mehta M, Patel Shah S, Shivhare V, Rath S, Kulshrestha A, T A, Singh J, Dash N, Patel D. PO-1346 Single Institute Retrospective Audit of protracted hypo-fractionated RT in Advanced Carcinoma Cervix. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)03310-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
18
|
Parikh A, Parkhurst M, Robbins P, Rosenberg S, Yang J. 190 Patient-derived tumor organoids reveal mechanisms of immune evasion which can guide decisions in adoptive cell therapy for common epithelial cancers. J Immunother Cancer 2021. [DOI: 10.1136/jitc-2021-sitc2021.190] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
Abstract
BackgroundAdoptive cellular transfer (ACT) of autologous tumor-infiltrating lymphocytes (TIL) is capable of inducing durable clinical responses in patients with advanced solid malignancies,1 however response rates are low. Limitations in personalized cancer modeling have been obstacles to understanding tumor-specific mechanisms of immune evasion. Patient-derived tumor organoids (PDTO) can be efficiently grown from common solid tumors and show genetic fidelity to whole exomic sequencing (WES) of the source tumor. We investigated their use in evaluating patient-specific immune responses in vitro and selecting T-cells for adoptive cellular immunotherapy.MethodsPDTO were established from metastatic deposits from patients with colorectal, breast, and pancreatic cancers and with their tumors of origin, were subjected to WES and RNAseq. They were then included in immunologic recognition assays with autologous TIL and cloned T-cell receptors (TCR) against shared mutations. TIL neoantigen reactivity was defined by screening against mutations using minigenes or synthetic peptides expressed by autologous antigen presenting cells.ResultsPDTO were successfully grown from 18/22 tumors from 15 patients. These cultures demonstrated a high degree of genetic fidelity to their parental tumors with near-complete retention of clonally expressed mutations. Organoid lines from 11 of these patients were utilized in recognition screening with autologous TIL or PBL transduced with relevant TCRs. TIL recognized 5/7 organoids tested, and this allowed the isolation and cloning of many of the TCRs responsible. Nineteen available TCRs predicted to be reactive with patient-specific neoantigens were also tested against relevant organoids, and only nine were found to be reactive. In most instances where such TCRs could not recognize organoid, tumor-specific defects in neoantigen processing or presentation or HLA-LOH events were either functionally or genetically identified.ConclusionsTo improve response rates to neoantigen-directed adoptive T-cell therapy, a better understanding of tumor immune evasion mechanisms is needed. The inability to grow autologous tumor lines from common epithelial cancers has been a major obstacle. We demonstrate that PDTO can be efficiently established and are genetically representative of their parental tumors. Importantly, these organoids can reveal defects in neoantigen processing or surface presentation as well as HLA loss-of-heterozygosity that would preclude immune recognition. PDTO may be a valuable tool for screening for tumor reactivity and selecting T-cells and TCRs for clinical use.Trial RegistrationThe study protocol was registered under https://clinicaltrials.gov under NCT00068003.ReferenceZacharakis N, Chinnasamy H, Black M, et al. Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer. Nat Med. 2018;24:724–730.Ethics ApprovalAll samples were derived from study participants who granted written, informed consent to be enrolled on a clinical protocol approved by the Institutional Review Board at the NCI (Bethesda, MD).
Collapse
|
19
|
Parikh A, Parikh S. Snapshots Quiz. Br J Surg 2021; 108:1180. [PMID: 34308468 DOI: 10.1093/bjs/znab236] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2021] [Accepted: 06/03/2021] [Indexed: 11/13/2022]
Affiliation(s)
- A Parikh
- Department of Gastroenterology, Lilavati Hospital and Research Centre, Bandra (West), Mumbai, India
| | - S Parikh
- Department of Gastroenterology, Lilavati Hospital and Research Centre, Bandra (West), Mumbai, India
| |
Collapse
|
20
|
Ratanchandani K, Kunikullaya S, Parikh A, Mehta M, Patel S, Shivhare V, Rath S, Modi V, Jain H, Anand D, Bathija N. PO-1038 Radiotherapy with Temozolomide for Pediatric Glioblastoma:A single institute retrospective analysis. Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)07489-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
21
|
Bathija N, Rathod H, Kunikullaya S, Parikh A, Mehta M, Patel S, Shivhare V, Rath S, Modi V, Jain H, Anand D, Ratanchandani K. PO-1211 Intraluminal brachytherapy boost in esophageal cancer: A single institute retrospective analysis. Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)07662-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
22
|
Gibson G, Rangasamy S, Contreras J, Singhvi A, Fox A, Moss N, Triveri M, Lala A, Mancini D, Itagaki S, Anyanwu A, Parikh A. Loeffler's Endocarditis Treated with Total Artificial Heart as Bridge to Transplant. J Heart Lung Transplant 2021. [DOI: 10.1016/j.healun.2021.01.2112] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
23
|
Cafri G, Gartner JJ, Zaks T, Hopson K, Levin N, Paria BC, Parkhurst MR, Yossef R, Lowery FJ, Jafferji MS, Prickett TD, Goff SL, McGowan CT, Seitter S, Shindorf ML, Parikh A, Chatani PD, Robbins PF, Rosenberg SA. mRNA vaccine-induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer. J Clin Invest 2021; 130:5976-5988. [PMID: 33016924 DOI: 10.1172/jci134915] [Citation(s) in RCA: 204] [Impact Index Per Article: 68.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2019] [Accepted: 07/29/2020] [Indexed: 12/30/2022] Open
Abstract
BACKGROUNDTherapeutic vaccinations against cancer have mainly targeted differentiation antigens, cancer-testis antigens, and overexpressed antigens and have thus far resulted in little clinical benefit. Studies conducted by multiple groups have demonstrated that T cells recognizing neoantigens are present in most cancers and offer a specific and highly immunogenic target for personalized vaccination.METHODSWe recently developed a process using tumor-infiltrating lymphocytes to identify the specific immunogenic mutations expressed in patients' tumors. Here, validated, defined neoantigens, predicted neoepitopes, and mutations of driver genes were concatenated into a single mRNA construct to vaccinate patients with metastatic gastrointestinal cancer.RESULTSThe vaccine was safe and elicited mutation-specific T cell responses against predicted neoepitopes not detected before vaccination. Furthermore, we were able to isolate and verify T cell receptors targeting KRASG12D mutation. We observed no objective clinical responses in the 4 patients treated in this trial.CONCLUSIONThis vaccine was safe, and potential future combination of such vaccines with checkpoint inhibitors or adoptive T cell therapy should be evaluated for possible clinical benefit in patients with common epithelial cancers.TRIAL REGISTRATIONPhase I/II protocol (NCT03480152) was approved by the IRB committee of the NIH and the FDA.FUNDINGCenter for Clinical Research, NCI, NIH.
Collapse
Affiliation(s)
- Gal Cafri
- Surgery Branch, National Cancer Institute (NCI), NIH, Bethesda, Maryland, USA.,Sheba Medical Center, Ramat Gan, Israel
| | - Jared J Gartner
- Surgery Branch, National Cancer Institute (NCI), NIH, Bethesda, Maryland, USA
| | - Tal Zaks
- Moderna Inc., Cambridge, Massachusetts, USA
| | | | - Noam Levin
- Surgery Branch, National Cancer Institute (NCI), NIH, Bethesda, Maryland, USA
| | - Biman C Paria
- Surgery Branch, National Cancer Institute (NCI), NIH, Bethesda, Maryland, USA
| | - Maria R Parkhurst
- Surgery Branch, National Cancer Institute (NCI), NIH, Bethesda, Maryland, USA
| | - Rami Yossef
- Surgery Branch, National Cancer Institute (NCI), NIH, Bethesda, Maryland, USA
| | - Frank J Lowery
- Surgery Branch, National Cancer Institute (NCI), NIH, Bethesda, Maryland, USA
| | - Mohammad S Jafferji
- Surgery Branch, National Cancer Institute (NCI), NIH, Bethesda, Maryland, USA
| | - Todd D Prickett
- Surgery Branch, National Cancer Institute (NCI), NIH, Bethesda, Maryland, USA
| | - Stephanie L Goff
- Surgery Branch, National Cancer Institute (NCI), NIH, Bethesda, Maryland, USA
| | - Christine T McGowan
- Surgery Branch, National Cancer Institute (NCI), NIH, Bethesda, Maryland, USA
| | - Samantha Seitter
- Surgery Branch, National Cancer Institute (NCI), NIH, Bethesda, Maryland, USA
| | | | - Anup Parikh
- Surgery Branch, National Cancer Institute (NCI), NIH, Bethesda, Maryland, USA
| | - Praveen D Chatani
- Surgery Branch, National Cancer Institute (NCI), NIH, Bethesda, Maryland, USA
| | - Paul F Robbins
- Surgery Branch, National Cancer Institute (NCI), NIH, Bethesda, Maryland, USA
| | - Steven A Rosenberg
- Surgery Branch, National Cancer Institute (NCI), NIH, Bethesda, Maryland, USA
| |
Collapse
|
24
|
Li M, Li Z, Kalinski P, Verschraegen C, Clinton S, Yang Y, Mortazavi A, Monk P, Folefac E, Yin M, Parikh A, Yang Y. 156P High TLR3 expression predicts improved survival in patients with clear cell renal cell carcinoma. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.277] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
25
|
Parikh A, Gugel E, Smolyakova N, Jen MH, Toms N, Lin Y, Kim J, Kopetz S. 455P A meta-analysis of efficacy and safety of cetuximab with biweekly vs. weekly dosing. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.566] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
26
|
Manivannan M, Sahu S, Dong K, Wang S, Gulati S, Parikh S, Beard N, Parikh A. Abstract 861: Improvements in variant calling sensitivity and specificity in single-cell DNA sequencing using deep learning. Cancer Res 2020. [DOI: 10.1158/1538-7445.am2020-861] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: It is now possible to interrogate thousands of cells in a single experiment for studying genetic variability with the advancements in single-cell sequencing technologies. Single-cell DNA platforms like Tapestri is still susceptible to errors from polymerase incorporations, structure induced template switching, PCR mediated recombination in Tapestri workflow or DNA-damage. Errors from sequencing could propagate from cluster amplification, cycle sequencing or image analysis. All together these errors can be divided into substitutions, insertions and deletion errors and can range from 0.5% to 2% depending on the sequencer. This makes rare variant and minimal residual disease detection challenging. To address these challenges, we developed deep learning models for correcting the errors, reduce false-positive rates and predict true variants.
Method: First we build a consensus sequence from several reads to predict the correct sequence. The initial layers learn the motifs and local sequence contexts in classifying the patterns. The output of this network is a probability distribution over possible bases and the prediction is the base with highest probability. The bases in the reads are subsequently corrected to the predicted base from the first step model. After error correcting the reads, we used the variants called by Genome Analysis Toolkit to feed into a multi-class classifier network. Our features consists of percent of cells mutated, and the different genotype features including depth, AF and quality of each variant in these cells. The truth labels are generated using tapestri instrument from multiple experiments with known bulk truth. We trained the network on over 200k cells from 13 samples and tested on a larger set of samples. Class imbalance was handled using upsampling the truth data. Our training samples include diverse samples from cell mixtures at various dilution uptill 0.1% and clinical samples processed through tapestri instrument and sequenced on a diverse set of sequencers including miseq and novaseq.
Conclusion: To validate this method, we used two different targeted panels on a Latin square model system with known truth mutations. With our 2-step workflow using error correction and variant prediction model, we significantly improved our median PPV 2-3 fold at 0.5% LOD while maintaining the sensitivity. We are further optimizing the model by adding more training samples and feature optimization.
Citation Format: Manimozhi Manivannan, Sombeet Sahu, Kim Dong, Shu Wang, Saurabh Gulati, Saurabh Parikh, Nigel Beard, Anup Parikh. Improvements in variant calling sensitivity and specificity in single-cell DNA sequencing using deep learning [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 861.
Collapse
Affiliation(s)
| | | | - Kim Dong
- Mission Bio, South San Francisco, CA
| | - Shu Wang
- Mission Bio, South San Francisco, CA
| | | | | | | | | |
Collapse
|
27
|
Gulati S, Wang S, Parikh S, Liu B, Gokhale K, Manivannan M, Sahu S, Kim D, Parikh A. Abstract 865: Using machine learning to detect heterogeneity in single cell multi-omics datasets. Cancer Res 2020. [DOI: 10.1158/1538-7445.am2020-865] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: While scRNA-seq helps in obtaining high-resolution views of single-cell heterogeneity through characterization of the functional state of cells, our understanding of the cellular properties and population architectures of heterogeneous tissues will be greatly advanced by the multi-omics investigation of single cells. Recently, several computational methods have been developed to integrate data from multiple different single cell experiments measuring individual analytes. But unambiguous inference that a cellular phenotype is caused by a genotype can only be achieved by their measurement from the same single cell. To address this gap, we have developed the Tapestri multi-omics workflow to analyze the RNA and DNA information from the same cell.
Methods: After pre-processing of the reads, cell calling is done by identifying the good barcodes using both DNA and RNA reads. DNA reads are processed to identify genetic variants in each cell. The variant cell matrix is then filtered for data completeness to ensure only high-quality data is used in downstream processing. Ploidy is estimated using by normalizing DNA reads, genetic variants and ploidy information together is used to identify subclones. The RNA reads are log normalized and scaled within each cell. Next we set the mean expression of each transcript to 0 and scale the variance to 1. This avoids downstream analysis being skewed by high expressors. We then trained a random forest classifier to identify significantly differentially expressed transcripts across subclones which were identified using genetic variants and ploidy information.
Results: Using the top differentially expressed transcripts we performed dimensionality reduction followed by clustering of cell types. The resulting visualization showed how well the genotypic and transcriptomic datasets integrated with one another. We tested this method on a model system with Raji and KG1 cell lines titrated at 50:50 ratio and were clearly able to associate the transcriptional variation with the genotypic variation of the 2 different cell lines. The method was also validated on a PBMC sample to ensure robustness of methods. We were able to identify the different cell types present the sample and were able to overlay that information with genetic variants to identify sub-clones in the identified cell types.
Citation Format: Saurabh Gulati, Shu Wang, Saurabh Parikh, Ben Liu, Kaustubh Gokhale, Manimozhi Manivannan, Sombeet Sahu, Dong Kim, Anup Parikh. Using machine learning to detect heterogeneity in single cell multi-omics datasets [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 865.
Collapse
Affiliation(s)
| | - Shu Wang
- Mission Bio, South San Francisco, CA
| | | | - Ben Liu
- Mission Bio, South San Francisco, CA
| | | | | | | | - Dong Kim
- Mission Bio, South San Francisco, CA
| | | |
Collapse
|
28
|
Corcoran R, Giannakis M, Allen J, Chen J, Pelka K, Chao S, Meyerhardt J, Enzinger A, Enzinger P, McCleary N, Yugelun M, Abrams T, Kanter K, Van Seventer E, Bradford W, Fetter I, Siravegna G, Tian J, Clark J, Ryan D, Hacohen N, Parikh A. SO-26 Clinical efficacy of combined BRAF, MEK, and PD-1 inhibition in BRAFV600E colorectal cancer patients. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.04.041] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
29
|
Stražar M, Žagar L, Kokošar J, Tanko V, Erjavec A, Poličar PG, Starič A, Demšar J, Shaulsky G, Menon V, Lemire A, Parikh A, Zupan B. scOrange-a tool for hands-on training of concepts from single-cell data analytics. Bioinformatics 2020; 35:i4-i12. [PMID: 31510695 PMCID: PMC6612816 DOI: 10.1093/bioinformatics/btz348] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
Motivation Single-cell RNA sequencing allows us to simultaneously profile the transcriptomes of thousands of cells and to indulge in exploring cell diversity, development and discovery of new molecular mechanisms. Analysis of scRNA data involves a combination of non-trivial steps from statistics, data visualization, bioinformatics and machine learning. Training molecular biologists in single-cell data analysis and empowering them to review and analyze their data can be challenging, both because of the complexity of the methods and the steep learning curve. Results We propose a workshop-style training in single-cell data analytics that relies on an explorative data analysis toolbox and a hands-on teaching style. The training relies on scOrange, a newly developed extension of a data mining framework that features workflow design through visual programming and interactive visualizations. Workshops with scOrange can proceed much faster than similar training methods that rely on computer programming and analysis through scripting in R or Python, allowing the trainer to cover more ground in the same time-frame. We here review the design principles of the scOrange toolbox that support such workshops and propose a syllabus for the course. We also provide examples of data analysis workflows that instructors can use during the training. Availability and implementation scOrange is an open-source software. The software, documentation and an emerging set of educational videos are available at http://singlecell.biolab.si.
Collapse
Affiliation(s)
- Martin Stražar
- Faculty of Computer and Information Science, University of Ljubljana, Ljubljana, Slovenia
| | - Lan Žagar
- Faculty of Computer and Information Science, University of Ljubljana, Ljubljana, Slovenia
| | - Jaka Kokošar
- Faculty of Computer and Information Science, University of Ljubljana, Ljubljana, Slovenia
| | - Vesna Tanko
- Faculty of Computer and Information Science, University of Ljubljana, Ljubljana, Slovenia
| | - Aleš Erjavec
- Faculty of Computer and Information Science, University of Ljubljana, Ljubljana, Slovenia
| | - Pavlin G Poličar
- Faculty of Computer and Information Science, University of Ljubljana, Ljubljana, Slovenia
| | - Anže Starič
- Faculty of Computer and Information Science, University of Ljubljana, Ljubljana, Slovenia
| | - Janez Demšar
- Faculty of Computer and Information Science, University of Ljubljana, Ljubljana, Slovenia
| | - Gad Shaulsky
- Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA
| | - Vilas Menon
- Janelia Research Campus, Howard Hughes Medical Institute, Ashburn, VA, USA
| | - Andrew Lemire
- Janelia Research Campus, Howard Hughes Medical Institute, Ashburn, VA, USA
| | | | - Blaž Zupan
- Faculty of Computer and Information Science, University of Ljubljana, Ljubljana, Slovenia.,Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA
| |
Collapse
|
30
|
Analogbei T, Dear N, Reed D, Esber A, Akintunde A, Bahemana E, Adamu Y, Iroezindu M, Maganga L, Kiweewa F, Maswai J, Owuoth J, Ake JA, Polyak CS, Crowell TA, Falodun O, Song K, Milazzo M, Mankiewicz S, Schech S, Golway A, Mebrahtu T, Lee E, Bohince K, Hamm T, Parikh A, Hern J, Lombardi K, Imbach M, Eller L, Peel S, Malia J, Kroidl A, Kroidl I, Geldmacher C, Kafeero C, Nambuya A, Tegamanyi J, Birungi H, Mugagga O, Nassali G, Wangiri P, Nantabo M, Nambulondo P, Atwijuka B, Asiimwe A, Nabanoba C, Semwogerere M, Mwesigwa R, Jjuuko S, Namagembe R, Bagyendagye E, Tindikahwa A, Rwomushana I, Ssentongo F, Kibuuka H, Millard M, Kapkiai J, Wangare S, Mangesoi R, Chepkwony P, Bor L, Maera E, Kasembeli A, Rotich J, Kipkoech C, Chepkemoi W, Rono A, Kesi Z, Ngeno J, Langat E, Labosso K, Langat K, Kirui R, Rotich L, Mabwai M, Chelangat E, Agutu J, Tonui C, Changwony E, Bii M, Chumba E, Korir J, Sugut J, Gitonga D, Ngetich R, Kiprotich S, Rehema W, Ogari C, Ouma I, Adimo O, Ogai S, Okwaro C, Maranga E, Ochola J, Obambo K, Sing'oei V, Otieno L, Nyapiedho O, Sande N, Odemba E, Wanjiru F, Khamadi S, Chiweka E, Lwilla A, Mkondoo D, Somi N, Kiliba P, Mwaipopo M, Mwaisanga G, Muhumuza J, Mkingule N, Mwasulama O, Sanagare A, Kishimbo P, David G, Mbwayu F, Mwamwaja J, Likiliwike J, Muhumuza J, Mcharo R, Mkingule N, Mwasulama O, Mtafya B, Lueer C, Kisinda A, Mbena T, Mfumbulwa H, Mwandumbya L, Edwin P, Olomi W, Adamu Y, Akintunde A, Tiamiyu A, Afoke K, Mohammed S, Harrison N, Agbaim U, Adegbite O, Parker Z, Adelakun G, Oni F, Ndbuisi R, Elemere J, Azuakola N, Williams T, Ayogu M, Enas O, Enameguono O, Odo A, Ukaegbu I, Ugwuezumba O, Odeyemi S, Okeke N, Umeji L, Rose A, Daniel H, Nwando H, Nicholas E, Iyanda T, Okolo C, Mene V, Dogonyaro B, Olabulo O, Akinseli O, Onukun F, Knopp G. Predictors and Barriers to Condom Use in the African Cohort Study. AIDS Patient Care STDS 2020; 34:228-236. [PMID: 32396478 DOI: 10.1089/apc.2019.0302] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Consistent condom use is an inexpensive and efficacious HIV prevention strategy. Understanding factors associated with condom use and barriers to use can inform strategies to increase condom uptake. The ongoing African Cohort Study prospectively enrolls adults at 12 clinical sites in Uganda, Kenya, Tanzania, and Nigeria. At enrollment, participants are asked about condom use at last sex with a regular partner. Robust Poisson regression models were used to evaluate predictors of self-reported condom use. Participants who reported not using condoms were asked to provide reasons. From January 2013 to September 2019, 2482 participants reported having at least one regular sexual partner in the preceding 6 months. Of those, 1577 (63.5%) reported using a condom at last sex. Condom use was more common among older participants, males, HIV-infected participants, and those with an HIV-infected partner. Married participants, those with a partner of unknown HIV status, and those reporting alcohol use were less likely to report condom use at last sex. Condom use at last sex also varied significantly by clinical site. Partner disapproval or refusal to use a condom was a consistent driver of disparities in condom use among participants who were HIV infected, female, and aged 18-24 years. Effective HIV prevention programs should integrate condom education with the tools necessary to negotiate condom use with regular partners.
Collapse
Affiliation(s)
- Tope Analogbei
- Health Implementation Program, Nigerian Ministry of Defense, Abuja, Nigeria
- US Army Medical Research Directorate—Africa, Abuja, Nigeria
| | - Nicole Dear
- US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland
- Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland
| | - Domonique Reed
- US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland
- Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland
| | - Allahna Esber
- US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland
- Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland
| | - Akindiran Akintunde
- US Army Medical Research Directorate—Africa, Abuja, Nigeria
- US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland
- Henry Jackson Foundation MRI, Abuja, Nigeria
| | - Emmanuel Bahemana
- US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland
- Henry Jackson Foundation MRI, Mbeya, Tanzania
| | - Yakubu Adamu
- US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland
- Henry Jackson Foundation MRI, Abuja, Nigeria
- US Army Medical Research Directorate—Africa, Nairobi, Kenya
| | - Michael Iroezindu
- US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland
- Henry Jackson Foundation MRI, Abuja, Nigeria
- US Army Medical Research Directorate—Africa, Nairobi, Kenya
| | - Lucas Maganga
- US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland
- National Institute of Medical Research—Mbeya Medical Research Centre, Mbeya, Tanzania
| | | | - Jonah Maswai
- US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland
- Kenya Medical Research Institute, Nairobi, Kenya
- Henry Jackson Foundation MRI, Kericho, Kenya
| | - John Owuoth
- US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland
- Kenya Medical Research Institute, Nairobi, Kenya
- Henry Jackson Foundation MRI, Kisumu, Kenya
| | - Julie A. Ake
- US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland
| | - Christina S. Polyak
- US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland
- Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland
| | - Trevor A. Crowell
- US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland
- Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Thalanayar Muthukrishnan P, Nouraie M, Parikh A, Holguin F. Zileuton use and phenotypic features in asthma. Pulm Pharmacol Ther 2019; 60:101872. [PMID: 31841698 DOI: 10.1016/j.pupt.2019.101872] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/20/2019] [Revised: 11/16/2019] [Accepted: 12/07/2019] [Indexed: 11/17/2022]
Abstract
Zileuton, a 5-lipoxygenase (5LPO) inhibitor exerts a broad influence in the arachidonic acid (AA) pathway by blocking upstream molecules that otherwise would lead to production of an array of inflammatory leukotrienes (LT) A4-E4. Hence, it has the potential to be a drug suitable to treat complicated asthmatics. Studies have shown modest response rates for zileuton in asthmatics. OBJECTIVE We sought to study our hypothesis that response to zileuton varies across specific asthmatic phenotypes. METHODS We retrospectively analyzed data from 129 patients with asthma that were prescribed zileuton at the University of Pittsburgh's Comprehensive Lung Clinic. A total of 75 patients from the above population had requisite lung function data and zileuton usage that would help assess a drug response effect. A zileuton responder was defined as having at least or greater than 5% annualized increase in post-bronchodilator FEV1% from baseline. Using a multivariate logistic regression analysis, we determined the association between responder status and the underlying phenotypic characteristics. RESULTS Using generalized estimating equations (GEE) analysis of 331 individual lung function test data-points as well as logistic regression analysis for predictors of 5% or more annualized increase in FEV1%, 21 of 75 patients (28%) met criteria for having a differential response to zileuton. Severe asthma was associated less often with responder status (OR 0.12; p 0.004). Obesity was less often associated with responder status, however did not reach significance (OR 0.46; p 0.15). CONCLUSION In this retrospective study, zileuton response varies across asthmatics, with poorer response rates being associated with those with severe asthma and possibly obesity. Although prescription trends for zileuton may predominate amongst severe asthmatics, this tendency does not seem to mirror the actual likelihood to respond. As against the trivial role for zileuton per current GINA algorithms, our study brings forward a notion that zileuton may well be considered along with LTRAs (like montelukast) for non-severe asthma.
Collapse
Affiliation(s)
| | - M Nouraie
- Departments of Medicine, University of Pittsburgh, Pittsburgh, PA, USA
| | - A Parikh
- University of Pittsburgh School of Public Health, Pittsburgh, PA, USA
| | - F Holguin
- Department of Pulmonary, Allergy and Critical Care Medicine, University of Pittsburgh Medical Center Pittsburgh, PA, USA
| |
Collapse
|
32
|
Italiano A, Cassier P, Roda D, Lin CC, Peltola K, Gazzah A, Shiah HS, Calvo E, Tosi D, Gao B, warburton L, Tanner M, Englert S, Lambert S, Parikh A, Afar D, Vosganian G, Moreno V. Safety and efficacy of anti-PD-1 inhibitor ABBV-181 in lung and head and neck carcinoma. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz253.113] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
33
|
Calvo E, Spira A, Prenen H, Ohe Y, Rottey S, Gazzah A, Millward M, Moreno V, Italiano A, Alanko T, Yoh K, Cassier P, Seto T, Afar D, Englert S, Komarnitsky P, Lambert S, Parikh A, Vosganian G, Gao B. Phase I open-label study evaluating the safety, pharmacokinetics, and preliminary efficacy of ABBV-181 and rovalpituzumab tesirine (ROVA-T) in patients with small cell lung cancer. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz264.012] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
34
|
Camidge D, Barlesi F, Goldman J, Morgensztern D, Heist R, Vokes E, Spira A, Angevin E, Su W, Hong D, Strickler J, Motwani M, Sun Z, Parikh A, Komarnitsky P, Wu J, Kelly K. MA14.03 EGFR M+ Subgroup of Phase 1b Study of Telisotuzumab Vedotin (Teliso-V) Plus Erlotinib in c-Met+ Non-Small Cell Lung Cancer. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.612] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
35
|
Ocampo C, Wu J, Dey J, Sun Z, Motwani M, Reddy A, Parikh A, Hay J, Komarnitsky P, Bach B. P2.01-19 Phase 2 Study of Telisotuzumab Vedotin (Teliso-V) in Previously Treated c-MET+ Non-Small Cell Lung Cancer: Trial in Progress. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1363] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
36
|
Pandya A, Yadav R, Suryanarayan U, Parikh A, Mehta M, Patel P, Mehta V, Kichloo A, Mankada D, Shah R, Rathod H. Retrospective Analysis of Radiotherapy with or Without Concurrent and Adjuvant Temozolomide in Newly Diagnosed Paediatric Diffuse Intrinsic Pontine Glioma. Int J Radiat Oncol Biol Phys 2019. [DOI: 10.1016/j.ijrobp.2019.06.1068] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
37
|
Parikh A, Van Seventer E, Boland G, Hartwig A, Jaimovich A, Raymond V, Talasaz A, Corcoran R. Serial assessment of cell-free circulating tumor DNA (ctDNA) to assess treatment effect and minimal residual disease during neoadjuvant and adjuvant therapy in colorectal cancer. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz154.015] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
38
|
Mauri G, Kanter K, Fish M, Horick N, Allen J, Blaszkowsky L, Clark J, Ryan D, Nipp R, Giantonio B, Goyal L, Dubois J, Murphy J, Roeland E, Weekes C, Wo J, Hong T, Zhu A, Van Seventer E, Corcoran R, Parikh A. PARP-ness in metastatic colorectal cancer. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz156.021] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
39
|
Parikh A, Kanter K, Mojtahed A, Schneider J, Van Seventer E, Fish M, Allen J, Blaszkowsky L, Wo J, Clark J, Giantonio B, Goyal L, Hong T, Nipp R, Roeland E, Weekes C, Zhu A, Ryan D, Fetter I, Horick N, Corcoran R. Serial circulating tumor DNA (ctDNA) monitoring to predict response to treatment in metastatic gastrointestinal cancers. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz156.007] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
40
|
Morita K, Wang F, Jahn K, Yan Y, Durruthy-Durruthy R, Parikh A, Matthews J, Little L, Gumbs C, Zhang J, Song X, Thompson E, Patel K, Bueso-Ramos C, DiNardo C, Ravandi F, Jabbour E, Andreeff M, Cortes J, Konopleva M, Garcia-Manero G, Kantarjian H, Eastburn DJ, Futreal PA, Beerenwinkel N, Takahashi K. Abstract 2725: The single-cell atlas of driver mutations in acute myeloid leukemia. Cancer Res 2019. [DOI: 10.1158/1538-7445.am2019-2725] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Assessment of intratumor genetic heterogeneity by next-generation sequencing (NGS) is confounded by tumor purity and zygosity of mutations. Furthermore, bulk NGS cannot visualize the cell-level co-occurrence or exclusivity among multiple mutations, causing the inaccurate inference of subclonal architecture. Here, we performed single cell DNA sequencing (scDNA seq) in 82 bone marrow samples from 70 patients with acute myeloid leukemia (AML) using a novel microfluidics-based platform covering 40 amplicons in 19 AML genes (Tapestri, Mission Bio). All samples were concurrently sequenced by the bulk NGS using 295 gene exome capture sequencing. Selected cases were also analyzed by SNP array (Illuminia Omni 2.5 array) to obtain allele-specific copy number data. In total, 319,406 cells (median 3,755 cells/sample) were genotyped with median allele drop-out rate of 8.7% (population frequency inferred from commonly heterozygous SNP loci). Each amplicon was covered at a median 24x/cell. The scDNA seq detected 230 of 238 (97%) bulk NGS-confirmed mutations. RUNX1 mutations were frequently detected as homozygous mutations and concurrent SNP array analysis detected copy number neutral loss-of-heterozygosity of RUNX1 in these cases. Additionally, in cases with homozygous FLT3-ITD mutations, SNP array detected allele-specific copy number gain of mutant loci, which likely resulted in homozygous calls. scDNA seq data unambiguously resolved the single-cell level co-occurrence of driver mutations in AML such as DNMT3A/FLT3-ITD/NPM1, SRSF2/IDH2, and ASXL1/RUNX1, confirming the cooperative function of these driver mutations. On the other hand, the data also revealed mutually exclusive relationships at cellular level between IDH1/IDH2, FLT3-ITD/TKD, NRAS/KRAS, NRAS/PTPN11, and SRSF2/EZH2 mutations, which supports the functional redundancy of these genes in leukemogenesis. Inference of phylogenetic trees using SCITE algorithm (Jahn et al. Genome Biology 2016) uncovered distinct patterns of clonal evolution in AML. The majority of the analyzed cases had a linear evolution pattern where the founder mutations linearly acquired sub-clonal mutations in a step-wise manner. We also detected convergent evolution in some cases where functionally similar driver mutations were acquired in parallel. DNMT3A, IDH1, IDH2 and U2AF1 mutations were frequently detected as trunk mutations, whereas FLT3, NRAS, and NPM1 mutations were usually detected as branch mutations. Analysis of longitudinal samples from 11 patients revealed the remodeling of clonal architecture at relapse. Patients who had 2 or more major subclones at baseline had significantly worse overall survival than those with one subclone (2-year OS 13 vs. 70 months, p = 0.0493). For the first time our data provides a comprehensive landscape of driver mutations and detailed clonal evolution history in AML at the single-cell level using high-throughput scDNA seq genotype information.
Citation Format: Kiyomi Morita, Feng Wang, Katharina Jahn, Yuanqing Yan, Robert Durruthy-Durruthy, Anup Parikh, Jairo Matthews, Latasha Little, Curtis Gumbs, Jianhua Zhang, Xingzhi Song, Erika Thompson, Keyur Patel, Carlos Bueso-Ramos, Courtney DiNardo, Farhad Ravandi, Elias Jabbour, Michael Andreeff, Jorge Cortes, Marina Konopleva, Guillermo Garcia-Manero, Hagop Kantarjian, Dennis J. Eastburn, P Andrew Futreal, Niko Beerenwinkel, Koichi Takahashi. The single-cell atlas of driver mutations in acute myeloid leukemia [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 2725.
Collapse
Affiliation(s)
- Kiyomi Morita
- 1The University of Texas MD Anderson Cancer Center, Houston, TX
| | - Feng Wang
- 1The University of Texas MD Anderson Cancer Center, Houston, TX
| | - Katharina Jahn
- 2Swiss Federal Institute of Technology in Zurich, Zurich, Switzerland
| | - Yuanqing Yan
- 3The University of Texas Health Science Center at Houston, Houston, TX
| | | | | | - Jairo Matthews
- 1The University of Texas MD Anderson Cancer Center, Houston, TX
| | - Latasha Little
- 1The University of Texas MD Anderson Cancer Center, Houston, TX
| | - Curtis Gumbs
- 1The University of Texas MD Anderson Cancer Center, Houston, TX
| | - Jianhua Zhang
- 1The University of Texas MD Anderson Cancer Center, Houston, TX
| | - Xingzhi Song
- 1The University of Texas MD Anderson Cancer Center, Houston, TX
| | - Erika Thompson
- 1The University of Texas MD Anderson Cancer Center, Houston, TX
| | - Keyur Patel
- 1The University of Texas MD Anderson Cancer Center, Houston, TX
| | | | | | - Farhad Ravandi
- 1The University of Texas MD Anderson Cancer Center, Houston, TX
| | - Elias Jabbour
- 1The University of Texas MD Anderson Cancer Center, Houston, TX
| | | | - Jorge Cortes
- 1The University of Texas MD Anderson Cancer Center, Houston, TX
| | | | | | | | | | | | - Niko Beerenwinkel
- 2Swiss Federal Institute of Technology in Zurich, Zurich, Switzerland
| | | |
Collapse
|
41
|
Parikh A, Clark J, Wo J, Yeap B, Allen J, Blaszkowsky L, Ryan D, Giantonio B, Weekes C, Zhu A, Van Seventer E, Ly L, Matlack L, Foreman B, Drapek L, Ting D, Corcoran R, Hong T. Proof of concept of the abscopal effect in MSS GI cancers: A phase 2 study of ipilimumab and nivolumab with radiation in metastatic pancreatic and colorectal adenocarcinoma. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz154.007] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
42
|
Manivannan M, Sahu S, Wang S, Kim D, Vissa N, Wilheim J, Sciambi A, Li N, Durruthy-Durruthy R, Parikh A, Jones K. Abstract 1663: Analytical methods to identify tumor heterogeneity and rare subclones in single cell DNA sequencing data from targeted panels. Cancer Res 2019. [DOI: 10.1158/1538-7445.am2019-1663] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Current bulk sequencing paradigms are inadequate to characterize complicated biological systems where somatic variation is buried in the landscape of populations. Single-cell DNA sequencing can simultaneously identify zygosity, rare alleles and determine whether mutations co-occur within the same cell. While high-throughput single-cell DNA analysis has been a recent innovation, it is essential to develop new capabilities for assessing genetic variation present in rare cells and to better understand the role that these cells play in the evolution of tumor progression. To address these challenges and enable the characterization of genetic diversity in cancer cell populations, we developed analytical methods to identify mutation signatures which define subclones present in a tumor population. Here we present a workflow for subclone identification using data generated on the Tapestri single-cell DNA platform. The analytical pipeline steps include obtaining raw reads from the sequencer, removing adapters, aligning and mapping the reads, calling individual cells, error correction of reads assigned to cells and identifying genetic variants within each cell. After filtering for high quality variants, we then filter for data completeness to ensure high quality data is used in downstream processing. The variant-cell matrix is then subjected to clustering to identify subclones. Top variants that define the signature of each subclone are also identified. To validate our methodology, we used data from two different targeted panels on different model systems with known truth mutations. Our pipeline shows the distinct clusters correlating with titration and cell line ratios. Cluster associated signature mutations were also identified. The pipeline can be used for multi sample analysis with time-series data from diagnosis to relapse or from primary site to metastasis to understand clonal diversity. These data demonstrate the utility of the Tapestri platform, the analytical pipeline, and associated data visualization capability. Our approach addresses key issues of identifying rare subpopulations of cells down to 0.1%, and transforms the ability to accurately characterize clonal heterogeneity in tumor samples. This high throughput method advances research efforts to improve patient stratification and therapy selection for various cancer indications.
Citation Format: Manimozhi Manivannan, Sombeet Sahu, Shu Wang, Dong Kim, Niranjan Vissa, Jordan Wilheim, Adam Sciambi, Nianzhen Li, Robert Durruthy-Durruthy, Anup Parikh, Keith Jones. Analytical methods to identify tumor heterogeneity and rare subclones in single cell DNA sequencing data from targeted panels [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 1663.
Collapse
Affiliation(s)
| | | | - Shu Wang
- Mission Bio, South San Francisco, CA
| | - Dong Kim
- Mission Bio, South San Francisco, CA
| | | | | | | | | | | | | | | |
Collapse
|
43
|
Cole R, Minto J, Flattery M, Parikh A, Dong T, Roy R, Bogar L, Morris A, Vega J, Gupta D, Bhatt K, Smith A, Laskar S, Lala A, Shah K, Shah P. Effects of Induction on the Risk of Post-Transplant De Novo DSA. J Heart Lung Transplant 2019. [DOI: 10.1016/j.healun.2019.01.986] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
44
|
Moss N, Parikh A, Rakita V, Lala A, Mitter S, Roldan J, Cuca A, Barghash M, Contreras J, Pinney S, Anyanwu A, Mancini D. Comparison of Exercise Hemodynamics in Patients Supported with Centrifugal and Axial Flow Left Ventricular Assist Devices. J Heart Lung Transplant 2019. [DOI: 10.1016/j.healun.2019.01.363] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
45
|
Urquhart O, Tampi MP, Pilcher L, Slayton RL, Araujo MWB, Fontana M, Guzmán-Armstrong S, Nascimento MM, Nový BB, Tinanoff N, Weyant RJ, Wolff MS, Young DA, Zero DT, Brignardello-Petersen R, Banfield L, Parikh A, Joshi G, Carrasco-Labra A. Nonrestorative Treatments for Caries: Systematic Review and Network Meta-analysis. J Dent Res 2018; 98:14-26. [PMID: 30290130 PMCID: PMC6304695 DOI: 10.1177/0022034518800014] [Citation(s) in RCA: 120] [Impact Index Per Article: 20.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
The goal of nonrestorative or non- and microinvasive caries treatment (fluoride-
and nonfluoride-based interventions) is to manage the caries disease process at
a lesion level and minimize the loss of sound tooth structure. The purpose of
this systematic review and network meta-analysis was to summarize the available
evidence on nonrestorative treatments for the outcomes of 1) arrest or reversal
of noncavitated and cavitated carious lesions on primary and permanent teeth and
2) adverse events. We included parallel and split-mouth randomized controlled
trials where patients were followed for any length of time. Studies were
identified with MEDLINE and Embase via Ovid, Cochrane CENTRAL, and Cochrane
Database of Systematic Reviews. Pairs of reviewers independently conducted the
selection of studies, data extraction, risk-of-bias assessments, and assessment
of the certainty in the evidence with the Grading of Recommendations Assessment,
Development, and Evaluation (GRADE) approach. Data were synthesized with a
random effects model and a frequentist approach. Forty-four trials (48 reports)
were eligible, which included 7,378 participants and assessed the effect of 22
interventions in arresting or reversing noncavitated or cavitated carious
lesions. Four network meta-analyses suggested that sealants + 5% sodium fluoride
(NaF) varnish, resin infiltration + 5% NaF varnish, and 5,000-ppm F (1.1% NaF)
toothpaste or gel were the most effective for arresting or reversing
noncavitated occlusal, approximal, and noncavitated and cavitated root carious
lesions on primary and/or permanent teeth, respectively (low- to
moderate-certainty evidence). Study-level data indicated that 5% NaF varnish was
the most effective for arresting or reversing noncavitated facial/lingual
carious lesions (low certainty) and that 38% silver diamine fluoride solution
applied biannually was the most effective for arresting advanced cavitated
carious lesions on any coronal surface (moderate to high certainty). Preventing
the onset of caries is the ultimate goal of a caries management plan. However,
if the disease is present, there is a variety of effective interventions to
treat carious lesions nonrestoratively.
Collapse
Affiliation(s)
- O Urquhart
- 1 Center for Evidence-Based Dentistry, Science Institute, American Dental Association, Chicago, IL, USA
| | - M P Tampi
- 1 Center for Evidence-Based Dentistry, Science Institute, American Dental Association, Chicago, IL, USA
| | - L Pilcher
- 1 Center for Evidence-Based Dentistry, Science Institute, American Dental Association, Chicago, IL, USA
| | - R L Slayton
- 2 Department of Pediatric Dentistry, School of Dentistry, University of Washington, Seattle, WA, USA
| | - M W B Araujo
- 3 Science Institute, American Dental Association, Chicago, IL, USA
| | - M Fontana
- 4 Department of Cariology, Restorative Sciences and Endodontics, School of Dentistry, University of Michigan, Ann Arbor, MI, USA
| | - S Guzmán-Armstrong
- 5 Advance Education Program in Operative Dentistry, University of Iowa, Iowa City, IA, USA
| | - M M Nascimento
- 6 Division of Operative Dentistry, Department of Restorative Dental Sciences, College of Dentistry, University of Florida, Gainesville, FL, USA
| | - B B Nový
- 7 DentaQuest Institute and DentaQuest Oral Health Center, Westborough, MA, USA
| | - N Tinanoff
- 8 Department of Orthodontics and Pediatric Dentistry, School of Dentistry, University of Maryland, College Park, MD, USA
| | - R J Weyant
- 9 Department of Dental Public Health and Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA
| | - M S Wolff
- 10 University of Pennsylvania, Philadelphia, PA, USA
| | - D A Young
- 11 Department of Diagnostic Sciences, Arthur A. Dugoni School of Dentistry, University of the Pacific, Stockton, CA, USA
| | - D T Zero
- 12 Department of Cariology, Operative Dentistry and Dental Public Health, Oral Health Research Institute, School of Dentistry Indiana University, Indianapolis, IN, USA
| | - R Brignardello-Petersen
- 13 Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada
| | - L Banfield
- 14 Health Sciences Library, McMaster University, Hamilton, ON, Canada
| | - A Parikh
- 15 College of Dental Medicine, Midwestern University, Downers Grove, IL, USA
| | - G Joshi
- 16 GC America, Alsip, IL, USA
| | - A Carrasco-Labra
- 1 Center for Evidence-Based Dentistry, Science Institute, American Dental Association, Chicago, IL, USA.,17 Evidence-Based Dentistry Unit and Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, University of Chile, Santiago, Chile
| |
Collapse
|
46
|
Powderly J, Cassier P, Cervantes A, Gao B, Gazzah A, Italiano A, Lin CC, Luke J, Moreno V, Peltola K, Rasco D, Spira A, Tanner M, Tosi D, Afar D, Englert S, Parikh A, Reddy A, Vosganian G, Tolcher A. Safety and efficacy of the PD-1 inhibitor ABBV-181 in patients with advanced solid tumors: Preliminary phase I results from study M15-891. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy279.425] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
47
|
Spira A, Chung K, Patnaik A, Tolcher A, Blaney M, Parikh A, Reddy A, Henner W, McDevitt M, Afar D, Powderly J. Safety, tolerability, and pharmacokinetics of the OX40 agonist ABBV-368 in patients with advanced solid tumors. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy288.022] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
48
|
Parikh A, Ali S, Moran A, Crilley P, Schrock A, Tan A, Reddy P, Miller V, Ross J, Zook S, Alvarez R, Markman M. Detection of targetable kinase fusions in 7260 patients in an integrated cancer system. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy269.076] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
49
|
Camidge R, Heist R, Goldman J, Angevin E, Strickler J, Morgensztern D, Barve M, Bauer T, Vokes E, Yi T, Motwani M, Parikh A, Wu J, Kelly K. An open-label, multicenter, phase I study of ABBV-399 (telisotuzumab vedotin, teliso-V) as monotherapy (T) and in combination with erlotinib (T+E) in non-small cell lung cancer (NSCLC). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy292.006] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
50
|
|